Zacks Investment Research
18 Jun 2026, 17:51 UTC · 22w ago
Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?
Impact · against what's priced in
Penumbra's receipt of the CE Mark for THUNDERBOLT provides a concrete catalyst for international growth and diversification. While regulatory approvals are often anticipated, the immediate transition from US FDA approval to European clearance expands the addressable market for their core stroke care technology.
- PEN+0.40
No priced-in read yet
- In context
The CE Mark approval for THUNDERBOLT in Europe, following last week's FDA approval, allows Penumbra to scale its computer-assisted vacuum thrombectomy technology in a major global market, building on an existing 16.5% year-over-year growth in international revenues.
Read from the article alone

Search tags




